New Oral Pill Cuts LDL Cholesterol 60% Without Statins: What Enlicitide Means for Heart Disease

# New Oral Pill Cuts LDL Cholesterol 60% Without Statins: What Enlicitide Means for Heart Disease

> **Quick answer:** Enlicitide, a once-daily pill developed by Merck, reduced LDL ("bad") cholesterol by 57% in a Phase 3 trial of 2,909 patients published in the New England Journal of Medicine in February 2026. It works via the same PCSK9 pathway as existing injectable drugs — but as a pill. The FDA granted it a priority voucher in December 2025. It is not yet approved, but it could reshape how millions of Americans manage high cholesterol, especially those who cannot tolerate statins.

*This article is for informational purposes only and does not replace professional medical advice. Consult a healthcare provider for medical concerns.*

The cholesterol drug conversation has been dominated by statins for 40 years. A new oral pill called enlicitide is now challenging that monopoly — and its Phase 3 trial results are unlike anything cardiologists have seen from a once-daily tablet. If you or someone you know struggles with high LDL despite diet changes or statin side effects, here is what the science actually says about enlicitide in 2026.

## What Is Enlicitide and How Does It Work?

Enlicitide decanoate is an oral PCSK9 inhibitor — the first of its kind. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that prevents your liver cells from clearing LDL cholesterol out of your blood. Block PCSK9, and the liver suddenly becomes dramatically better at pulling LDL out of circulation.